As the AGM approaches, I urge everyone here who is a shareholder to carefully consider your vote on the remuneration report. As a shareholder, I believe it’s our responsibility to ensure that Cynata’s executive pay aligns with company performance and is transparent. Unfortunately, Cynata falls short in two critical areas:
Lack of Alignment with Performance: Executive remuneration should reflect Cynata’s performance and progress. However, expected trial result announcements continue to be delayed, no partnership has been secured, and our cash position is weakening. With the increased likelihood of raising funds through new equity placements, long-term shareholders face further dilution.
Insufficient Transparency of KPIs: Shareholders have never had visibility into the Key Performance Indicators (KPIs) set for our executives, yet bonuses are continually paid out for meeting these undisclosed targets. Without transparency, shareholders cannot confirm whether incentives are genuinely performance-based or aligned with long-term value creation.
For these reasons, I encourage you to vote against the remuneration report and hold our leadership accountable for delivering real results and transparency.
- Forums
- ASX - By Stock
- Voting Against Resolution 1 - Adoption of Remuneration Report
CYP
cynata therapeutics limited
Add to My Watchlist
6.33%
!
21.0¢

As the AGM approaches, I urge everyone here who is a shareholder...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
21.0¢ |
Change
0.013(6.33%) |
Mkt cap ! $47.45M |
Open | High | Low | Value | Volume |
20.5¢ | 21.0¢ | 20.0¢ | $43.06K | 208.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 52500 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 4548 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 52500 | 0.200 |
1 | 23589 | 0.195 |
3 | 67575 | 0.190 |
2 | 196958 | 0.175 |
3 | 191956 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 4548 | 1 |
0.230 | 1495 | 1 |
0.235 | 64191 | 1 |
0.240 | 7474 | 1 |
0.245 | 1000 | 1 |
Last trade - 15.46pm 21/08/2025 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, MD & CEO
Michael Thurn
MD & CEO
SPONSORED BY The Market Online